3 New Strong Buy Ratings from Top-Rated Analysts: 08/21/2025

By Mijuško Šibalić, Stock Market Writer and Stock Researcher
August 21, 2025 6:41 AM UTC
3 New Strong Buy Ratings from Top-Rated Analysts: 08/21/2025

Oh happy day — here’s a peek at the latest picks from our Strong Buy Stocks from Top Wall Street Analysts screener:

  • Why a top-rated analyst forecasts 35%+ upside for NerdWallet (NRDS
  • Alert: There’s a big upcoming catalyst for Zymeworks (ZYME
  • Past Stock of the Week pick US Foods Holding Corp (USFD) is back on the list

P.S. Get more alerts like this daily … Try WallStreetZen Premium.


A note from our sponsors...

Analysts Project a $14 Share Price, You Can Invest for $3.50 Wall Street's bullish on the AI company making heart disease easier to detect-but you won't find this opportunity on the Nasdaq. HeartSciences (Nasdaq: HSCS) is offering investors $3.50 investment units that include one convertible preferred share and one warrant-providing investors two potential common shares. Based on some Wall Street analysts' projections, that amounts to a near-term 500% return potential. Learn More and Invest in HeartSciences This is a paid advertisement for HeartSciences Regulation A+ offering. Please read the offering circular at invest.heartsciences.com.

1. NerdWallet (NASDAQ: NRDS

NerdWallet is a competitor of ours — but we strive to be even-handed. Despite underperforming revenue expectations in its last quarterly report, the company boasts a strong checkbook, and Wall Street analysts are expecting plenty of upside here — to boot, NRDS is currently trading at a pretty appealing valuation.

Zen Rating: A (Strong Buy)see full analysis >  

Recent Price: $10.08get current quote > 

Max 1-year forecast: $17.00 

Why we’re watching:

  • At the moment, five analysts issue ratings for NRDS shares — their coverage is split between 3 Strong Buy ratings and 2 Hold ratings. See the ratings
  • The average price target for NerdWallet stock, currently pegged at $13.80, implies a 36.9% upside.
  • Youssef Squali of Truist Securities (a top 1% rated analyst) maintained a Strong Buy rating on NerdWallet after the company reported its Q2 2025 earnings, but slashed his price forecast from $19 to $17. Squali’s revised price target is still the highest one on the Street, however.
  • Squali pointed to the "mixed" quarter in revenue missed as the key driver behind his decision.
  • The analyst explained that a change in platform partner in the quarter caused a slowdown in Insurance revenue, accounting for the top-line miss.
  • That said, better expense management accounted for the earnings beat, Squali said.
  • Performance in other segments remained relatively consistent sequentially, with Banking the bright spot, the analyst added.
  • NerdWallet is currently the 2nd highest-rated stock in the Internet Content & Information industry, which has an Industry Rating of A.
  • NRDS has a Zen Rating of A and ranks in the top 1% of stocks — in fact, it is currently the 15th highest rated stock out of the more than 4,600 that our system tracks.
  • NerdWallet shares rank in the 85th percentile when it comes to Growth, as well as the 87th percentile in Sentiment.
  • NRDS ranks even higher in terms of Artificial Intelligence and Financials — in the top 10% and 8%, respectively, to be precise.
  • However, Value is NerdWallet’s strongest suit —as the stock is trading at an attractive 25.85x price-to-earnings (P/E) ratio, it comes as little surprise that it ranks in the top 4% in this category. (See all 7 Zen Component Grades here >)

2. Zymeworks (NASDAQ: ZYME

Zymeworks is a clinical-stage biopharmaceutical company focused on improving the efficacy and safety of cancer treatments. The company develops programs both in-house and through partnerships with major pharma players — so it enjoys a broad and diverse pipeline. However, the main draw here is quite specific — and it has to do with the smart money crowd.

Zen Rating: B (Buy)see full analysis >  

Recent Price: $14.36 get current quote > 

Max 1-year forecast: $22.00 

Why we’re watching:

  • ZYME is an under-the-radar pick — only 2 Wall Street analysts track the stock and issue ratings for it. The coverage is evenly split between a single Strong Buy rating and a single Hold rating. See the ratings
  • Yigal Nochomovitz of Citigroup (a top 10% rated analyst) recently maintained a Strong Buy rating on the stock, and increased his price target from $19 to a Street-high $22. 
  • Hiking their price target, Nochomovitz told readers that Citigroup believes Zanidatamab is gaining traction in biliary tract cancer.
  • The stock price's next catalyst will be late Q4's HERIZON data, the analyst predicted.
  • ZYME ranks in the top 10% of the stocks that we track based on a holistic analysis of 115 factors, giving it a Zen Rating of B.
  • In terms of the stock’s Growth Component Grade rating, it ranks in the top 4% of equities.
  • However, Sentiment is where Zymeworks truly shines. While the stock doesn’t enjoy extensive coverage, our Sentiment Component Grade rating also takes into account factors such as short interest and insider selling. That last one is the key here — in the last 12 months, a whopping 98.19% of insider transactions involving ZYME have been purchases — so key company personnel and investors alike are confident that the stock will produce outsized returns. (See all 7 Zen Component Grades here >)


A note from our sponsors...

Wall Street Just Got a New Gold Standard-Discover NatGold Tokens Wall Street is tokenizing everything-but NatGold just unlocked a $20 trillion gold reserve without digging a single ounce. Digitally mined, backed by verified in-ground gold, this asset class is designed for the digital age. Reserve now and get a guaranteed 10% discount-only for the first 10,000 early adopters. Reserve your NatGold Tokens today and lock in your 10% discount before Wall Street catches on.

3. US Foods Holding Corp (NYSE: USFD

A recent Stock of the Week selection is back on the list! US Foods Holding distributes food — whether fresh, frozen, or dry, to food service companies all across the United States. While it is faced with a tough macro environment, it stands out as quite a safe pick in a tumultuous market.

Zen Rating: A (Strong Buy)see full analysis >  

Recent Price: $76.35 get current quote >

Max 1-year forecast: $96.00 

Why we’re watching:

  • US Foods Holding Corp shares have 7 Strong Buy ratings and 1 Hold rating. See the ratings
  • In addition, the average price target of $89 implies a healthy 16.57% upside.
  • Wells Fargo equity researcher Edward Kelly (a top 8% rated analyst) maintained a Strong Buy rating on USFD following the company’s Q2 2025 earnings, and increased his price target from $80 to $87.
  • Kelly called the results a "solid beat and raise quarter," but noted that the likelihood of a PFGC deal took a hit in management's earnings call commentary, and case volume performance missed a higher bar.
  •  For their part, however, the analyst argued that the US Foods Holding story remains compelling under the noise. 
  • US Foods Holding Corp is the 2nd highest-rated stock in the Food Distribution industry, which has an Industry Rating of A.
  • USFD ranks in the top 5% of the equities we track, giving it a Zen Rating of A.
  • US Foods Holding Corp ranks in the 74th percentile of stocks in terms of Growth, and the 75th percentile when it comes to Value.
  • According to its Artificial Intelligence Component Grade rating, USFD ranks in the top 20% of equities. It also ranks in the top 16% according to Financials.
  • With that being said, Safety is the star of the show — in this category, US Foods Holding Corp ranks in the top 4%. (See all 7 Zen Component Grades here >)

What to Do Next?

Want to get in touch? Email us at news@wallstreetzen.com.

WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.